Suominen (SUY1V) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 1.3% YoY to €101.1m and comparable EBITDA increased to €5.1m from €3.4m; operating cash flow was -€8.5m.

• Higher production, lower fixed costs and early Full Potential Program benefits supported profitability; 9M net sales declined 4.7% to €302.3m while comparable EBITDA rose to €11.6m.

Financial highlights

• Q3 operating loss was €0.5m versus €0.8m; net loss was €3.1m versus €2.0m, and comparable operating profit improved to €1.0m from a €0.7m loss.

• 9M operating loss widened to €6.7m from €2.7m, and net loss was €11.8m versus €8.2m; higher comparability items contributed to the operating-loss increase.

• Q3 comparable EBITDA increased €1.6m YoY to €5.1m; 9M comparable EBITDA rose €0.9m to €11.6m, while reported EBITDA fell to €5.5m from €10.0m.

• Q3 included €1.6m of comparability-affecting costs, mainly Full Potential Program consulting and severance; 9M costs totaled €6.1m.

Outlook and guidance

• 2026 comparable EBITDA guidance remains unchanged, with improvement expected from 2025’s €12.6m.

• Full Potential Program Phase I targets a 10% EBITDA margin, with Phase II ambition above 10%; planned investment is ~€30m, including ~€10m transformation costs and ~€20m capex.

• Alicante ALI55 production ramp-up is expected to continue through the rest of 2026 and into 2027; demand is available, with production ramp-up the constraint.

• Excess raw-material inventories are expected to normalize mainly in Q4 and by Q1 at the latest.